News for KalVista Pharmaceuticals, Inc. (4XC1.F)

KalVista Pharmaceuticals, Inc. (KALV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, m...

Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, multiple ...

KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 ...

Today's Daily Dose brings you news about KalVista's hereditary angioedema trial results, Heat Biologics' encouraging data from its phase II trial of HS-110 in non-small cell lung cancer, Gamida's presentation of full efficacy and safety results of Omidubicel in patients with hematologic malignancies and Neovasc regaining Nasdaq compliance.

KalVista Shares More Than Double on Drug Test Results, Stocks: KALV,TAK,PHAR, release date:Feb 09, 2021

KalVista Shares More Than Double on Drug Test Results, Stocks: KALV,TAK,PHAR, release date:Feb 09, 2021

Shares of KalVista Pharmaceuticals, Inc. (KALV) surged over 135% on Tuesday morning after the drug maker reported positive results from a mid-stage trial of treatment for hereditary angioedema attacks.